Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation?

Hypertension

Volumn 43, Issue 4, 2004, Pages 739-745

  Kuwahara, Fumitaka ^a   Kai, Hisashi ^a   Tokuda, Keisuke ^a   Takeya, Motohiro ^b   Takeshita, Akira ^c   Egashira, Kensuke ^c   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Diastole; Fibrosis; Hypertension; Macrophages

Indexed keywords

MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA CONSTRICTION; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MODEL; FIBROBLAST; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HYPERTENSION; INFLAMMATION; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AORTIC VALVE STENOSIS; CHEMOKINE CCL2; DIASTOLE; ENDOMYOCARDIAL FIBROSIS; FIBROBLASTS; HYPERTENSION; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; MACROPHAGES; MALE; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 1642542466     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000118584.33350.7d     Document Type: Article

References (23)

1. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.
2. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-348.
3. Mann DL, Mechanisms and models in heart failure. Circulation. 1999;100:999-1008.
4. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. TGF-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-135.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
6. Hinglais N, Heudes D, Nicoletti A. Colocalization of myocardial fibrosis and inflammatory cells in rats. Lab Invest. 1994;70:286-294.
7. Nicoletti A, Heudes D, Mandet C, Hinglais N, Bariety J, Michel JB. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertcnsive rats. Cardiovasc Res. 1996;32:1096-1107.
8. Kuwahara K, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, Takcmiya K, Jalalidin A, Koga M, Nagata T, Shibata R, Imaizumi T. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension. 2003;41:819-823.
9. Reap TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213-225.
10. Capers Q IV, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor R. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997;30:1397-1402.
11. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A. Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation. 2000;102:2243-2249.
12. Kuwahara F, Kai H, Tokuda K, Shibata R, Kusaba K, Tahara N, Niiyama H, Nagata T, Imaizumi T. Hypoxia-inducible factor-1α/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension. 2002;39:46-50.
13. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998;83:594-601.
14. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade. Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 1997;30:1621-1627.
15. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattracmnt protein-1/monocyte chemoattractant and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306-314.
16. Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl RAK. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-β. Kidney Int. 1999;56:135-144.
17. Border WA, Nobel NA. Transforming growth factor-β in tissue fibrosis. N Eng J Med. 1994;331:1286-1292.
18. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41:532-543.
19. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Biol Chem. 1993;122:103-111.
20. Kolattukudy PE, Quach T BS, Breckenridge S, Hensley J, Altschuld R, Gordillo G, Klenotic S, Orosz C, Parker-Thornburg J. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol. 1998;152:101-111.
21. Gu L, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. Chem Immunol. 1999;72:7-29.
22. Porreca E, DiFebbo C, Reale M, Castellani ML, Baccante G, Barbacane R, Conti P, Cuccurullo F, Poggi A. Monocyte chemoattractant protein (MCP)-1 is a mitogen for cultured vascular smooth muscle cells. J Vasc Res. 1997;34:58-65.
23. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspectives. Hypertens. 1995;25:155-161.